Regulatory

Feb 01, 2011
Pharmaceutical Executive
The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
Jan 01, 2011
Pharmaceutical Executive
Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead
Dec 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Cegedim survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spend
Dec 01, 2010
Pharmaceutical Executive
Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research
Nov 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
A timeline of some of the landmark legislation, court decisions, and drug scandals that helped forge the FDA
Nov 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Harvard professor Daniel Carpenter offers a piercing analysis of the FDA and sheds light on its biggest challenges
Aug 25, 2010
By Pharmaceutical Executive Editors
Results from a new study reveal that patients taking Takeda's diabetes treatment Actos have the same rate and kind of side effects as GSK's embattled Avandia. Is this a good sign?
Aug 04, 2010
By Pharmaceutical Executive Editors
In the wake of FDA's refusal to approve the lead drug in NicOx's pipeline, the French firm has decided to close its US headquarters.
Jul 14, 2010
By Pharmaceutical Executive Editors
Vivus's weight-loss drug Qnexa is heading into an FDA review with the backing of generally positive study data. Will FDA give the thumbs up? Depends on how severe it thinks the side effects are.
Jul 08, 2010
By Pharmaceutical Executive Editors
With a long, hard fight looming, President Obama decided to go around Congress to install Don Berwick, founder of the Institute for Healthcare Improvement, as the top administrator of the Centers for Medicaid and Medicare Services.
native1_300x100
lorem ipsum